[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=97d4ce8aec9eda1546a099da170a0a585c28a21881cd0a643349db4c0abbca7a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740587820,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
      "id": 132884878,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=97d4ce8aec9eda1546a099da170a0a585c28a21881cd0a643349db4c0abbca7a"
    }
  },
  {
    "ts": null,
    "headline": "Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales",
    "summary": "Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Read more here.",
    "url": "https://finnhub.io/api/news?id=52e85af7218e9d86070665db8e5d73325ff79bb8fb6db12cc9dd03bfc5432724",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740571931,
      "headline": "Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales",
      "id": 132879234,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2176459835/image_2176459835.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Read more here.",
      "url": "https://finnhub.io/api/news?id=52e85af7218e9d86070665db8e5d73325ff79bb8fb6db12cc9dd03bfc5432724"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Oncology Strength: Beating Wall Street Again",
    "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
    "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740561344,
      "headline": "Merck's Oncology Strength: Beating Wall Street Again",
      "id": 132878313,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/151810706/image_151810706.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
      "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b"
    }
  }
]